Strategic Pharma Partnering Yiviva has an active memorandum of understanding with AstraZeneca to develop platforms, technologies, and innovative therapeutics using a systems biology approach, signaling interest in deeper co-development and strategic alliances with a major pharma partner.

Academic Credibility Backed by Yale University and with recognition at a leading SAPA event, Yiviva carries strong academic credibility and industry visibility that can accelerate partnerships, joint research programs, and grant opportunities.

Aging Therapeutics Focus Focusing on aging-associated diseases, particularly oncology and gastroenterology, positions Yiviva in high-growth therapeutic areas and creates openings for early collaboration on platforms, translational studies, or companion diagnostics in aging populations.

Small Team Flexibility A lean organizational footprint suggests flexibility and a reliance on external collaborations, making Yiviva a viable candidate for platform licensing, CRO partnerships, and milestone-driven development deals.

Monetization Opportunities With early-stage revenue, there is potential to monetize IP through licensing or co-development agreements leveraging the systems biology platform and aging-focused therapeutics as value propositions for pharma partners.